Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSIT: Naloxegol for Postoperative Ileus in Cardiac Surgery
NCT04433390Phase 3Completed
- Sponsor
- CMC Ambroise Paré
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative ileus (POI) comparing Naloxegol group with Placebo group (2 arms). Primary endpoint: Duration of postoperative ileus at 5 days. Started Oct 2020; status: completed.
02
Drugs
naloxegol
03
Conditions
postoperative ileus (POI)
Beyond the preview
Go deeper on NCT04433390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04433390.